 "Aurobindo Pharma")
Aurobindo Pharma has received final approval from the USFDA to manufacture and market its Tranexamic acid injection, used for treating hemophilia, in the American market.
The company plans to launch the product by the end of this fiscal. It is in the WHO list of essential medicines.
